Autres domaines


Laboratory tests and imaging studies in patients with cutaneous malignant melanoma - 09/09/11

Doi : 10.1016/S0190-9622(98)70324-X 
Carol L. Huang, MDb, Nathalie Provost, MDa, Ashfaq A. Marghoob, MDb, Alfred W. Kopf, MDa, Ludmila Levin, BAa, Robert S. Bart, MDa
New York and Huntington, New York 
From The Ronald O. Perelman Department of Dermatology, New York University School of Medicine and the Oncology Section, Charles C. Harris Skin and Cancer Pavilion, New York University Medical Center, New York City ; The New York University Melanoma Cooperative Groupa; and the Department of Dermatology, State University of New York at Stony Brookb and the Pigmented Lesion and Skin Cancer Section, Huntington Medical Group, Huntington 


Laboratory tests and imaging studies are often ordered for asymptomatic patients with malignant melanomas (MMs) in an effort to detect subclinical metastatic disease. However, their sensitivity and specificity for detecting cryptic metastases are not well established. A review of the literature on laboratory tests and imaging studies for MM metastases was undertaken to address the usefulness of such investigations in asymptomatic patients with MM in AJCC (American Joint Committee on Cancer system of classification) stages I, II, and III. A review of the pertinent literature since 1966 was conducted through MEDLINE, Medica, and Cancerlit. Laboratory tests and imaging studies revealed occult MM metastases in only a small number of the thousands of reported patients with putative AJCC stage I, II, and III MM. However, for those diagnosed with limited metastases, surgical removal with or without immunotherapy, chemotherapy, or radiotherapy can lead to long-term remissions in some patients. For patients with asymptomatic AJCC stage I or II disease, chest roentgenograms (CXR) and blood lactic dehydrogenase (LDH) levels may be obtained at low cost and prove to be of benefit if metastases are identified. For patients with AJCC stage III disease, computed tomographic (CT) scans of the thorax, abdomen, and pelvis (especially when the primary cutaneous site of the melanoma is below the waist) may be considered for detecting metastatic MM. Other tests, such as magnetic resonance imaging (MRI) scans of the brain, may be ordered based on symptoms or physical findings. In the future, technologically improved techniques and newer methods may prove cost-effective for detecting treatable asymptomatic MM metastases. Furthermore, improvement in treatments will also influence the indications for the search for occult MM metastases. At this time there is a need for an international consensus conference on laboratory tests and imaging studies for occult melanoma metastases. (J Am Acad Dermatol 1998;39:451-63.)

Le texte complet de cet article est disponible en PDF.


 Supported by The Ronald O. Perelman Department of Dermatology, New York University School of Medicine; the Department of Dermatology, State University of New York at Stony Brook; the Joseph H. Hazen Foundation; the Niarchos Fund of the Skin Cancer Foundation; the Mary and Emanuel Rosenfeld Foundation; and the Kaplan Comprehensive Cancer Center (Cancer Center Support Core Grant No 5P30CA-16087-18).
 Reprints are not available from the authors.
 0190-9622/98/$5.00 + 0  16/1/91564

© 1998  American Academy of Dermatology, Inc. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer

    Export citations

  • Fichier

  • Contenu

Vol 39 - N° 3

P. 451-463 - septembre 1998 Retour au numéro
Article précédent Article précédent
  • Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: Effects on the duration of improvement
  • Mark Lebwohl, Ayelet Yoles, Kathleen Lombardi, Wendy Lou
| Article suivant Article suivant
  • Cyclosporine consensus conference: With emphasis on the treatment of psoriasis
  • Mark Lebwohl, Charles Ellis, Alice Gottlieb, John Koo, Gerald Krueger, Kenneth Linden, Jerome Shupack, Gerald Weinstein

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?


Mon compte

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.